AR064494A1 - Variantes de lipasa para uso farmaceutico - Google Patents

Variantes de lipasa para uso farmaceutico

Info

Publication number
AR064494A1
AR064494A1 ARP070105859A ARP070105859A AR064494A1 AR 064494 A1 AR064494 A1 AR 064494A1 AR P070105859 A ARP070105859 A AR P070105859A AR P070105859 A ARP070105859 A AR P070105859A AR 064494 A1 AR064494 A1 AR 064494A1
Authority
AR
Argentina
Prior art keywords
lipases
lipase
pharmaceutical use
protease
diabetes
Prior art date
Application number
ARP070105859A
Other languages
English (en)
Spanish (es)
Original Assignee
Novozymes As
Novozymes Biotech Inc
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As, Novozymes Biotech Inc, Solvay Pharm Gmbh filed Critical Novozymes As
Publication of AR064494A1 publication Critical patent/AR064494A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ARP070105859A 2006-12-21 2007-12-21 Variantes de lipasa para uso farmaceutico AR064494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87119606P 2006-12-21 2006-12-21

Publications (1)

Publication Number Publication Date
AR064494A1 true AR064494A1 (es) 2009-04-08

Family

ID=38043020

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105859A AR064494A1 (es) 2006-12-21 2007-12-21 Variantes de lipasa para uso farmaceutico

Country Status (16)

Country Link
US (3) US8273348B2 (enExample)
EP (6) EP2455461B1 (enExample)
JP (1) JP5406040B2 (enExample)
KR (1) KR20090101930A (enExample)
CN (2) CN101743308B (enExample)
AR (1) AR064494A1 (enExample)
AU (1) AU2007337150A1 (enExample)
BR (1) BRPI0721103A2 (enExample)
CA (3) CA2670643C (enExample)
IL (1) IL198893A0 (enExample)
MX (1) MX2009006597A (enExample)
NO (1) NO20092729L (enExample)
RU (1) RU2009128067A (enExample)
TW (1) TW200829698A (enExample)
WO (1) WO2008079685A2 (enExample)
ZA (1) ZA200903598B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407693T1 (de) 2004-03-22 2008-09-15 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin,mit tensiden
BRPI0614914A2 (pt) 2005-07-29 2011-04-19 Solvay Pharm Gmbh processos para a fabricação de pó de pancreatina esterilizada
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US8273348B2 (en) 2006-12-21 2012-09-25 Novozymes A/S Lipase variants for pharmaceutical use
US20090217464A1 (en) * 2008-02-29 2009-09-03 Philip Frank Souter Detergent composition comprising lipase
MX2010009464A (es) 2008-02-29 2010-09-22 Dsm Ip Assets Bv Lipasas con alta especificidad hacia acidos grasos de cadena corta y usos de las mismas.
US9163203B2 (en) * 2008-02-29 2015-10-20 Novozymes A/S Lipolytic enzyme variant with improved stability and polynucleotides encoding same
EP4159833A3 (en) 2009-12-09 2023-07-26 The Procter & Gamble Company Fabric and home care products
CN103703139A (zh) 2011-07-22 2014-04-02 诺维信北美公司 用于预处理纤维素材料和改进其水解的方法
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
ES2887576T3 (es) * 2011-12-29 2021-12-23 Novozymes As Composiciones detergentes con variantes de lipasa
US9394530B2 (en) * 2012-02-03 2016-07-19 Novozymes A/S Lipase variants and polynucleotides encoding same
CN107988181A (zh) * 2012-04-02 2018-05-04 诺维信公司 脂肪酶变体以及编码其的多核苷酸
EP2906691B1 (en) * 2012-10-12 2021-01-27 Danisco US Inc. Compositions and methods comprising a lipolytic enzyme variant
CN105209612A (zh) * 2013-05-14 2015-12-30 诺维信公司 洗涤剂组合物
ES2956266T3 (es) * 2013-07-19 2023-12-18 Danisco Us Inc Composiciones y procedimientos que comprenden una variante de enzima lipolítica
WO2016079305A1 (en) * 2014-11-20 2016-05-26 Novozymes A/S Alicyclobacillus variants and polynucleotides encoding same
CN107002054A (zh) 2014-12-05 2017-08-01 诺维信公司 脂肪酶变体以及编码它们的多核苷酸
US11268076B2 (en) 2014-12-09 2022-03-08 Novozymes A/S Lipase variants and polynucleotides encoding same
CN107864658A (zh) 2015-04-07 2018-03-30 诺维信公司 用于选择具有脂肪酶活性的酶的方法
WO2017001673A1 (en) * 2015-07-01 2017-01-05 Novozymes A/S Methods of reducing odor
US10760037B2 (en) * 2015-07-03 2020-09-01 Novozymes A/S Sulfite compositions
US11326152B2 (en) 2016-07-18 2022-05-10 Novozymes A/S Lipase variants, polynucleotides encoding same and the use thereof
WO2018139634A1 (ja) * 2017-01-30 2018-08-02 学校法人日本医科大学 アデノ随伴ウイルス（ａａｖ）キャプシドタンパク質の変異体
CA3073362A1 (en) 2017-09-27 2019-04-04 Novozymes A/S Lipase variants and microcapsule compositions comprising such lipase variants
US11286443B2 (en) * 2017-09-27 2022-03-29 The Procter & Gamble Company Detergent compositions comprising lipases
CN111801416A (zh) * 2018-02-08 2020-10-20 诺维信公司 脂肪酶变体及其组合物
US12269847B2 (en) * 2018-08-16 2025-04-08 Donaldson Company, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
CN111334369B (zh) * 2020-03-11 2022-10-21 陕西科技大学 一种酶法制备卵磷脂型pufa的方法
CN115803083A (zh) * 2020-06-24 2023-03-14 基利安股份公司 新脂肪酶
US20240035005A1 (en) * 2020-10-29 2024-02-01 Novozymes A/S Lipase variants and compositions comprising such lipase variants
CN113846074B (zh) * 2021-10-20 2022-10-21 南京林业大学 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用
CN119630280A (zh) 2022-05-14 2025-03-14 诺维信公司 用于预防、处理、抑制和/或消除植物病原性侵染和感染的组合物和方法
WO2023247664A2 (en) * 2022-06-24 2023-12-28 Novozymes A/S Lipase variants and compositions comprising such lipase variants

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
DE69129988T2 (de) * 1990-09-13 1999-03-18 Novo Nordisk A/S, Bagsvaerd Lipase-varianten
US5869438A (en) 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
DK46693D0 (enExample) 1993-04-23 1993-04-23 Novo Nordisk As
BR9107206A (pt) 1990-12-05 1993-11-03 Novo Nordisk As Processo para produzir uma variante de proteina que evoca uma resposta imunogenica diminuida em animais,produtos obtidos,composicao e uso
JPH06507071A (ja) 1991-05-01 1994-08-11 ノボザイムス アクティーゼルスカブ 安定化酵素
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
US5866526A (en) 1993-10-04 1999-02-02 Novo Nordisk A/S Enzyme preparation comprising a modified enzyme
DE69527835T2 (de) 1994-02-22 2003-04-10 Novozymes A/S, Bagsvaerd Methode zur herstellung einer variante eines lipolytischen enzymes
AU3924095A (en) 1994-11-24 1996-06-17 Novo Nordisk A/S A process for producing polypeptides with reduced allergenicity
WO1996017929A1 (en) 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
CN1165614C (zh) 1995-01-26 2004-09-08 诺沃奇梅兹有限公司 含有木聚糖酶的动物饲料添加剂
US6495357B1 (en) * 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
WO1997004078A1 (en) 1995-07-14 1997-02-06 Novo Nordisk A/S A modified enzyme with lipolytic activity
DE69632538T2 (de) 1995-08-11 2005-05-19 Novozymes A/S Neuartige lipolytische enzyme
CA2277618A1 (en) 1997-01-10 1998-07-16 Novo Nordisk A/S Enzyme coupled with polymeric molecules for skin care
EP1017794A1 (en) 1997-02-06 2000-07-12 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
WO1999000489A1 (en) 1997-06-25 1999-01-07 Novo Nordisk A/S A modified polypeptide
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
DE69931607T2 (de) * 1998-02-17 2007-05-16 Novozymes A/S Lipasevariante
CA2346929A1 (en) 1998-10-13 2000-04-20 Novozymes A/S A modified polypeptide with reduced immune response
CN1206237C (zh) 1998-10-30 2005-06-15 诺沃奇梅兹有限公司 低免疫原性蛋白质变体
JP2002531067A (ja) 1998-10-30 2002-09-24 ノボザイムス アクティーゼルスカブ 低下したアレルゲン性を有するグリコシル化タンパク質
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
WO2000032758A1 (en) 1998-11-27 2000-06-08 Novozymes A/S Lipolytic enzyme variants
DE50002450D1 (de) 1999-03-17 2003-07-10 Solvay Pharm Gmbh Enzyme zur behandlung von diabetes mellitus typ i
EP1171581A1 (en) 1999-03-31 2002-01-16 Novozymes A/S Lipase variant
EP1428874B1 (en) 1999-03-31 2013-12-18 Novozymes A/S Lipase variant
CN100429990C (zh) 2000-02-08 2008-11-05 Dsmip资产公司 酸-稳定性蛋白酶在动物饲料中的用途
AU2001254620A1 (en) * 2000-04-28 2001-11-12 Novozymes A/S Lipolytic enzyme variant
CA2431972C (en) 2001-01-10 2012-10-23 Novozymes A/S Thermostable lipolytic enzyme variant
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
CA2432329C (en) 2001-02-07 2012-04-10 Novozymes A/S Lipase variants
US20050255544A1 (en) 2002-01-16 2005-11-17 Novozymes A/S Lipolytic enzyme variants and method for their production
BRPI0407108A (pt) 2003-02-06 2006-01-24 Novozymes As Método para produzir uma imunoglobulina funcional humana
DK1625216T3 (da) * 2003-05-09 2013-03-18 Novozymes As Lipolytiske enzymvarianter
WO2004111216A2 (en) * 2003-06-19 2004-12-23 Novozymes A/S Phospholipase variants
US20060236414A1 (en) 2003-06-19 2006-10-19 Novozymes A/S Proteases and methods for producing them
JP2007535913A (ja) 2004-01-21 2007-12-13 ノボザイムス アクティーゼルスカブ ヘテロカリオン菌類又は菌類宿主細胞におけるモノクローナル抗体の生成
ATE407693T1 (de) 2004-03-22 2008-09-15 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin,mit tensiden
SI2198880T1 (sl) 2004-10-14 2017-02-28 Eli Lilly And Co. Sestavki, ki vsebujejo lipazo, proteazo in amilazo, za zdravljenje pankreasne insuficience
WO2006084470A2 (en) 2005-02-10 2006-08-17 Novozymes A/S Enzymatic enantioselective ester or amide hydrolysis or synthesis
RU2007149045A (ru) * 2005-06-24 2009-07-10 Новозимс А/С (Dk) Липазы для фармацевтического применения
US8017351B2 (en) 2005-06-24 2011-09-13 Novozymes A/S Amylases for pharmaceutical use
NZ563777A (en) 2005-06-24 2010-08-27 Novozymes As Serine protease derived from Bacillus licheniformis optionally in combination with lipases and amylases for pharmaceutical use
WO2007080197A2 (en) * 2006-01-16 2007-07-19 Novozymes A/S Immobilised enzymes
EP2371948B1 (en) * 2006-01-23 2017-04-19 Novozymes A/S Lipase variants
JP2009523900A (ja) * 2006-01-23 2009-06-25 ザ プロクター アンド ギャンブル カンパニー リパーゼと漂白剤触媒を含む組成物
US8273348B2 (en) * 2006-12-21 2012-09-25 Novozymes A/S Lipase variants for pharmaceutical use

Also Published As

Publication number Publication date
EP2455461B1 (en) 2016-03-16
IL198893A0 (en) 2010-02-17
US9539311B2 (en) 2017-01-10
EP2455459B1 (en) 2016-03-16
BRPI0721103A2 (pt) 2014-03-04
CA2961041C (en) 2020-07-14
CN101743308B (zh) 2015-09-16
EP2261328A1 (en) 2010-12-15
CA2961041A1 (en) 2008-07-03
EP2455460A3 (en) 2012-12-26
US20100034797A1 (en) 2010-02-11
ZA200903598B (en) 2010-04-28
EP2455462B1 (en) 2016-03-16
EP2455461A2 (en) 2012-05-23
WO2008079685A2 (en) 2008-07-03
US20120308543A1 (en) 2012-12-06
EP2261328B1 (en) 2013-11-20
US9029115B2 (en) 2015-05-12
WO2008079685A3 (en) 2008-11-06
CA2670643A1 (en) 2008-07-03
EP2455462A2 (en) 2012-05-23
CA3081308A1 (en) 2008-07-03
EP2099907A2 (en) 2009-09-16
KR20090101930A (ko) 2009-09-29
RU2009128067A (ru) 2011-01-27
US8273348B2 (en) 2012-09-25
EP2455459A2 (en) 2012-05-23
EP2455460A2 (en) 2012-05-23
CA3081308C (en) 2024-02-20
TW200829698A (en) 2008-07-16
CN101743308A (zh) 2010-06-16
EP2455462A3 (en) 2013-05-29
EP2455459A3 (en) 2013-04-24
EP2455461A3 (en) 2013-05-29
JP5406040B2 (ja) 2014-02-05
AU2007337150A1 (en) 2008-07-03
US20150209414A1 (en) 2015-07-30
CN105112386A (zh) 2015-12-02
NO20092729L (no) 2009-09-18
CA2670643C (en) 2017-04-25
MX2009006597A (es) 2009-07-02
JP2010512795A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
AR064494A1 (es) Variantes de lipasa para uso farmaceutico
AR053634A1 (es) Lipasas para uso farmaceutico
Li et al. Cordycepin inhibits LPS-induced inflammatory and matrix degradation in the intervertebral disc
Petrosino et al. N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities
BRPI0510817A (pt) protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
Shen et al. Mutational analysis of structural features of rat hormone-sensitive lipase
AR032392A1 (es) Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
Paula et al. Modulation of the peroxiredoxin system by cytokines in insulin-producing RINm5F cells: down-regulation of PRDX6 increases susceptibility of beta cells to oxidative stress
ECSP088758A (es) Métodos para reducir la aglomeración de proteína
EP4413994A3 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
CL2017000498A1 (es) Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013)
EP4241854A3 (en) Lysosomal storage disease enzyme
JP2010512795A5 (enExample)
GB2497715A (en) Preparation and use of combination enzyme and gastriontestinal modulator delivery systems
AR063570A1 (es) Efectos biologicos mejorados para composiciones que comprenden acido rosmarinico
BR112012000914B8 (pt) uso de polipeptídeo com atividade condrogênica, método in vitro de indução da diferenciação de células-tronco mesenquimais em condrócitos, e composição farmacêutica para aplicação intra-articular
Bhatta et al. Angiotensin II-induced arterial thickening, fibrosis and stiffening involves elevated arginase function
AR071261A1 (es) Variantes de proteasa para uso farmaceutico
BRPI0922653B8 (pt) uso de uma lipase bacteriana do tipo pseudomonas em solução aquosa
Gidlöf Toward a new paradigm for targeted natriuretic peptide enhancement in heart failure
AR078291A1 (es) Composiciones de enzimas pancreaticas y metodos para tratar pancreatitis e insuficiencia pancreatica
Xiao et al. The protein kinase C cascade regulates recruitment of matrix metalloprotease 9 to podosomes and its release and activation
WO2006136160A3 (en) Proteases for pharmaceutical use
EP1961816A4 (en) NEW HIGH-FUNCTIONAL ENZYME WITH MODIFIED SUBSTRATE SPECIFICITY

Legal Events

Date Code Title Description
FA Abandonment or withdrawal